Feb 13 (Reuters) - Australian pharmaceutical behemoth CSL Ltd said on Wednesday its first-half profit grew 10.1 percent following stronger drug sales in the United States, and raised its full-year guidance to the upper end of an earlier provided range.
Net profit for the six months to Dec. 31 came in at $1.2 billion on a constant currency basis, compared with $1.1 billion last year, Australia’s fifth-largest listed company said in a statement.
CSL said it now expected fiscal 2019 net profit to be around the upper end of the previously provided range of $1.88 billion to $1.95 billion on a constant currency basis.
The company, which does significant business in the United States, declared an interim dividend of 85 cents per share, up from 79 cents last year.
Reporting by Ambar Warrick in Bengaluru Editing by Matthew Lewis